La Jol­la CEO de­camps just as biotech faces a reck­on­ing for iron over­load drug

Months af­ter tout­ing how LJPC-401 ap­pears to sig­nif­i­cant­ly low­er ex­cess iron lev­els in a small study in­volv­ing pa­tients with hered­i­tary he­mochro­mato­sis, La Jol­la Phar­ma­ceu­ti­cal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.